Maxim Group downgraded Mast Therapeutics Inc (NASDAQ:MSTX) to Hold in a report released today.
- Updated: September 24, 2016
Maxim Group has downgraded Mast Therapeutics Inc (NASDAQ:MSTX) to Hold in a report released on 9/21/2016.
Just yesterday Mast Therapeutics Inc (NASDAQ:MSTX) traded -4.28% lower at $0.11. Mast Therapeutics Inc’s 50-day moving average is $0.44 and its 200-day moving average is $0.37. The last stock price is down -65.95% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 23,151,235 shares of MSTX traded hands, up from an average trading volume of 7,334,930
Recent Performance Chart
Mast Therapeutics Inc has 52 week low of $0.10 and a 52 week high of $0.71 and has a total market value of $0.
Brief Synopsis About Mast Therapeutics Inc (NASDAQ:MSTX)
Mast Therapeutics, Inc. is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options. The Company's segment is engaged in the business of developing therapies for serious or life-threatening diseases. The Company focuses on its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, its lead product candidate. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. The Company's AIR001 is in Phase II clinical development for the treatment of patients with HFpEF.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.